Home > News and media > Publications > Publications archive > 2011 > Intellectual Property, Pharmaceuticals And Public Health: access to drugs in developing countries


Intellectual Property, Pharmaceuticals And Public Health: access to drugs in developing countries

Page Contents >

Kenneth C Shadlen, Samira Guennif, Alenka Guzmán, and N Lalitha (eds)
Edward Elgar (2011)

This up-to-date book examines pharmaceutical development, access to medicines, and the protection of public health in the context of two fundamental changes that the global political economy has undergone since the 1970s, the globalisation of trade and production and the increased harmonization of national regulations on intellectual property rights.

With authors from eleven different countries presenting case studies of national experiences in Africa, Asia and the Americas, the book analyses national strategies to promote pharmaceutical innovation, while at the same time assuring widespread access to medicines through generic pharmaceutical production and generic pharmaceutical importation. The expert chapters focus on patents as well as an array of regulatory instruments, including pricing and drug registration policies.

Presenting in-depth analysis and original empirical research, this book will strongly appeal to academics and students of intellectual property, international health, international political economy, international development and law.

Full table of contents:

1. Globalization, Intellectual Property Rights, and Pharmaceuticals: Meeting the Challenges to Addressing Health Gaps in the New International Environment
Kenneth C Shadlen, Samira Guennif, Alenka Guzmán and N Lalitha

2. Pharmaceutical Production and Access to Essential Medicines in South Africa
Heinz Klug

3. Intellectual Property and Access to Medicines: Paradoxes in Moroccan Policy
Gaëlle Krikorian

4. The Invisible Threat: Trade, Intellectual Property, and Pharmaceutical Regulations in Colombia
Tatiana Andia

5. The Challenges of Constructing Pharmaceutical Capabilities and Promoting Access to Medicines in Mexico under TRIPS
Alenka Guzmán

6. Corporate Power and State Resistance: Brazil’s Use of TRIPS Flexibilities for its National AIDS Program
Matthew Flynn

7. The Politics of Patents and Drugs in Brazil and Mexico: The Industrial Bases of Health Policies
Kenneth C Shadlen

8. Pharmaceutical Patent Policy in Developing Countries: Learning from the Canadian Experience
Jean-Frédéric Morin and Mélanie Bourassa Forcier

9. Access to Indian Generic Drugs: Emerging Issues
N Lalitha

10. Sufficient but Expensive Drugs: A Double-Track System that Facilitated Supply Capability in China
Mariko Watanabe and Luwen Shi

11. Access to Essential Drugs in Thailand: Intellectual Property Rights and Other Institutional Matters Affecting Public Health in a Developing Country
Samira Guennif

12. The TRIPS Agreement and Health Innovation in Bangladesh
Padmashree Gehl Sampath


  • Dr Ken Shadlen is a reader in development studies in the Department of International Development at LSE.

Purchase this book from the publishers|


'This impressive collection offers fascinating new perspectives on the impact of pharmaceutical patents on access to medicines in developing countries. The volume’s editors have put together an important book that sets out clearly the challenges to public health in a wide range of national contexts. The book will be a valuable text for all scholars and decision-makers interested in the global politics of intellectual property rights and public health.'
Duncan Matthews, Queen Mary, University of London, UK

'Since the 1970s the pharmaceutical industry has undergone significant changes in its research and development paradigm, trade and production. Regulatory frameworks have also changed substantially, particularly in the area of intellectual property rights. This book provides much needed empirical evidence on the impact of these and other changes on the pharmaceutical sector and on access to medicines in developing countries. The studies, conducted with a common methodology, on nine developing countries (including major producers of pharmaceuticals such as China and India) and on Canada, make an outstanding contribution to the literature in the field. The data and analysis in the book are of immediate interest to policy makers and to scholars in various fields, including innovation economics, industrial policy, health systems and intellectual property.'
Carlos Correa, University of Buenos Aires, Argentina

Intellectual Property, Pharmaceuticals And Public Health